Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia-Reference-Cited by-同舟云学术

Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia

Published:2012-03 Issue:3 Volume:36 Page:316-323
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Abdelhamid Emna,Preudhomme Claude,Helevaut Nathalie,Nibourel Olivier,Gardin Claude,Rousselot Philippe,Castaigne Sylvie,Gruson Bérengère,Berthon Céline,Soua Zohra,Renneville Aline

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference41 articles.

1. Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia;Buccisano;Blood,2010

2. Sensitive measurement of quantity dynamics of FLT3 internal tandem duplication at early time points provides prognostic information;Chou;Annals of Oncology,2011

3. Monitoring of minimal residual disease in acute myeloid leukemia;Kern;Cancer,2008

4. The role of FLT3 in the haematopoietic malignancies;Stirewalt;Nature Reviews Cancer,2003

5. Cooperating gene mutations in acute myeloid leukemia: a review of the literature;Renneville;Leukemia,2008

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ultrasensitive quantitation of FLT3-ITD mutation in patients with acute myeloid leukemia using ddPCR;Molecular Biology Reports;2023-06-10

2. Molecular MRD Assessment in Acute Myeloid Leukemias;Indian Journal of Medical and Paediatric Oncology;2023-04-17

3. NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia;International Journal of Hematology;2022-04-04

4. Role of Minimal Residual Disease Testing in Acute Myeloid Leukemia;Clinics in Laboratory Medicine;2021-09

5. Molecular methods for measurable residual disease in acute myeloid leukemia: where are we and where are we going?;Journal of Hematopathology;2021-01-08